

Good Ventures Foundation
c/o 314 Lytton Avenue, Suite 200
Palo Alto, CA 94301

Dr Henning Gädeke Chair of the Global Health EDCTP3 Joint Undertaking Governing Board
c/o Dr Michael Makanga Executive Director Global Health EDCTP3 Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d’Or
1060 Brussels
Belgium

August 28, 2025

Letter of endorsement

Dear Dr. Gädeke and Dr. Makanga ,

Good Ventures Foundation is pleased to submit this letter of endorsement in support of the SPOTLIGHT project, submitted under the Global Health EDCTP3 Joint Undertaking (GH EDCTP3 JU) by the Statens Serum Institut (SSI).

Good Ventures Foundation is a mission-driven philanthropic funder that supports scalable, cost-effective interventions to address major global health burdens, including tuberculosis. We recognize the urgent need for affordable, effective TB vaccines, particularly those compatible with large-scale rollout in low- and middle-income countries (LMICs).

To support this goal, Good Ventures Foundation has awarded a one-year grant of \$847,779.90 effective June 26, 2025 to SSI to help develop and validate a new manufacturing process of the H107e vaccine antigen for protection against pulmonary tuberculosis. We understand this to be a core component of the H107/CAF®10b vaccine candidate.

Our grant reflects our commitment to supporting sustainable and equitable health innovations, and our support of SSI on the H107/CAF®10b vaccine candidate reflects our desire to support the development of a novel vaccine for tuberculosis. Our grant also reflects our and SSI’s commitment to equitable and global access by ensuring that the results of the research that we fund is broadly disseminated.

We are happy to learn of SSI’s application to the Global Health EDCTP3 Joint Undertaking. Importantly, we understand that the H107 manufacturing activities supported by our grant funding are integrated and in synergy with the proposed SPOTLIGHT project activities related to the adjuvant component (CAF®10b). We hope that the coordinated progression of both the antigen and the adjuvant components of the H107/CAF®10b vaccine candidate will help ensure harmonized development and help to de-risks future clinical and regulatory milestones

We agree to keep all non-public information we receive related to SSI’s participation in the Global Health EDCTP3 JU confidential. This confidentiality obligation will apply in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. Internal dissemination of information within our organisation or to our affiliates or advisors will be done on the basis of the “need-to-know” principle. We are also happy to work with the Global Health EDCTP3 JU to provide any additional information related to our contribution.

Good Ventures Foundation
c/o 314 Lytton Avenue, Suite 200
Palo Alto, CA 94301

Sincerely,

Signed by:

E0F15876A076478...
Sarah Li
Authorized Signatory